I know you bought it at the very very bottom... and of course sold it all at the ultimate top... so now its a pos. I got to get a bucket of money.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GZFX DIPPING HERE
real
News for 'VION' - (Vion Initiates Phase II Trial of CLORETAZINE(TM)
(VNP40101M) In Patients with Acute Myeloid Leukemia or Myelodysplastic
Syndromes)
NEW HAVEN, Conn., Mar 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- VION
PHARMACEUTICALS, INC. (Nasdaq: VION) announced today that it had initiated
a
Phase II trial of its anticancer agent CLORETAZINE(TM) (VNP40101M) as a
single
agent in patients with acute myeloid leukemia (AML) or myelodysplastic
syndromes
(MDS).
Vion expects to accrue up to a total of 80 patients to the trial, which
will be
conducted in multiple sites in the U.S. and Europe. The objective of the
study
is to determine the response rate of CLORETAZINE(TM) (VNP40101M) in the
following patient groups: patients with AML or high-risk MDS (high-risk
indicates disease with poor prognostic characteristics) who are older than
60
years old and have not received prior chemotherapy; and AML patients of
any age
who have relapsed after a first complete remission that lasted less than
twelve
months.
Dr. Mario Sznol, Vice President, Clinical Affairs, stated, "Despite the
substantial amount of prior treatment for most patients in the Phase I
trial of
CLORETAZINE(TM) (VNP40101M) in advanced hematologic malignancies, evidence
of
activity was demonstrated, and CLORETAZINE(TM) (VNP40101M) was well-
tolerated.
Therefore, we are optimistic that in the current Phase II trial, which
includes
patients with less prior treatment, CLORETAZINE(TM) (VNP40101M) will show
promising single-agent activity."
He added, "We also hope to confirm the good safety profile for
CLORETAZINE(TM)
(VNP40101M) which would make the drug attractive in the elderly population
and
create an opportunity for more effective treatment in combination with
standard
agents. This trial is an important component of the overall development
plan for
CLORETAZINE(TM) (VNP40101M)."
CLORETAZINE(TM) (VNP40101M) has been evaluated in four Phase I trials to
date,
two in leukemia and two in solid tumors. Of these trials, a Phase I trial
of
CLORETAZINE(TM) (VNP40101M) in combination with Ara-C in patients with
advanced
leukemia continues to accrue patients. Results from this trial will be
presented
at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
in
June 2004.
In March 2004, the U.S. Food and Drug Administration designated
CLORETAZINE(TM)
(VNP40101M) as a fast track program in relapsed or refractory acute
myeloid
leukemia.
Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of
cancer. Vion has two agents in clinical trials: Triapine(R), a potent
inhibitor
of a key step in DNA synthesis and CLORETAZINE(TM) (VNP40101M), a unique
sulfonyl hydrazine alkylating agent. Vion is also developing and has an
option
to license several heterocyclic hydrazones which have demonstrated potent
anti-tumor activity in preclinical studies. Additional agents in
preclinical
studies include: KS119, a hypoxia-selective compound from the sulfonyl
hydrazine
class and TAPET(R), a modified Salmonella vector used to deliver
anticancer
agents directly to tumors. For additional information on Vion and its
product
development programs, visit the Company's Internet web site at
www.vionpharm.com.
This news release contains forward-looking statements. Such statements are
subject to certain risk factors which may cause Vion's plans to differ or
results to vary from those expected, including Vion's ability to secure
external
sources of funding to continue its operations, the inability to access
capital
and funding on favorable terms, continued operating losses and the
inability to
continue operations as a result, its dependence on regulatory approval for
its
products, delayed or unfavorable results of drug trials, the possibility
that
favorable results of earlier clinical trials are not predictive of safety
and
efficacy results in later clinical trials, the need for additional
research and
testing, and a variety of other risks set forth from time to time in
Vion's
filings with the Securities and Exchange Commission, including but not
limited
to the risks discussed in Vion's Annual Report on Form 10-K for the year
ended
December 31, 2002. Except in special circumstances in which a duty to
update
arises under law when prior disclosure becomes materially misleading in
light of
subsequent events, Vion does not intend to update any of these
forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
COMPANY CONTACT: Vion Pharmaceuticals, Inc.
Howard B. Johnson, President
(203) 498-4210 phone
SOURCE Vion Pharmaceuticals, Inc.
CONTACT: Howard B. Johnson, President of Vion Pharmaceuticals,
Inc.,
+1-203-498-4210
URL: http://www.vionpharm.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
-0-
KEYWORD: Connecticut
INDUSTRY KEYWORD: MTC
HEA
BIO
Source: Comtext Market News
Compliments of Scottrade.com
Wish I did ...LOL I got the SHEETS again.....
real
MAIL CALL VION ISSUES SHARES
News for 'VION' - (DJ Vion Pharmaceuticals Registers 17.2M Shrs For Hldrs
>VION)
WASHINGTON (Dow Jones)--Vion Pharmaceuticals Inc. (VION)
registered
about 17.2 million shares for certain shareholders who may sell the shares
from time to time.
The number of shares being offered includes 3,688,463 shares which
are issuable upon the exercise of warrants, according to a registration
statement filed Monday with the Securities and Exchange Commission.
Vion Pharmaceuticals said it won't receive any proceeds from the
sale
of the shares other than the exercise price payable upon the exercise of
the
warrants.
Vion said it issued the shares and warrants to the selling
stockholders in a private transaction.
Vion, based in New Haven, Conn., develops therapeutics and
technologies for the treatment of cancer.
-By Donna Hemans; Dow Jones Newswires; 202-862-1344;
donna.hemans@dowjones.com
(END) Dow Jones Newswires
03-29-04 1225ET- - 12 25 PM EST 03-29-04
Source: DJ Broad Tape
Compliments of Scottrade.com
WNMI DILLUTION? Anyone have an opinion?
real
Its a little past Jiggy...LOL
Anybody picking up any JRVR?
real
GZFX 23mil shares by lunch served.
real
here is a GZFX shake
real
I bought in and it went down...I am keeoping my eye on it. Anybody holding for teh long play?
real
anybody think WNMI might run a little today?
real
Ya think omni, I was going to sell @.166 but the buying @ .168 seemed very strong... It looks like it goes up every time they get to shake out shares
real
WNMI can't get a fill
real
WNMI is it worth a hit today
real
GXFX next stop .175
real
GZFX is a delima I dump enoough and am riding free shares ....
real
you think its goin gto hold?
real
Report the problem to the webmaster of the GZFX board.
real
You might have a ad pointer on your system... it replaces your search with a competitor website automatic.
real
Why don't you tell us guy? We can use another point of view.
real
LOL
WHT after hours can anyone see it?
real
It looks like the Aroon is ready for the second hiccup
real
see now I have been told oppisite...mmmm
real
It could go both ways... that is a really long pennant.... and pretty equal and straight. But it has been in the .05 region at one time .... worth a hairy eyeball. A long tightening pennant can lead to explosive breakouts so I am told.
That chart is like a coiled snake tighter and tighter.
real
LOL
real
Taking applications for a board secretary. In 50 words please submit to billy why you would be a good board secretary.
real
:) that a 4 good buddy LOL
MY percentage is 89.5% picking them Right... RIGHT BEFORE THEY GO DOWN <joking> HAAAAAAA haaaaaaaaaa
real.
It can sell for 65.00 they all are POS's LOL By the way NETFLIX split 2 for 1 @ 65.00
real
1.8 or 2 million that is splittin hairs... they are hoping to have 2.5 mil by the end of next year. Another important thing is subscriber churn. How many ae coming in to how many are leaving month to month. earnings third and forth quarter is going to show how things are. Summer is a bad time for DVD rentals anyway people are outside more, But good for Video Games, kids are off from school
real
Remember GZFX is a POS and a good little doggie... A POS that has a few rides left in it. :)
real
Ok guys...Netflix has been in business how long? Right you are and they have reportedly 1.8 million subscribers if you believe the rags and mags.
What will be critical for GZFX is how long till they get 1 mil customers. What would be great if people prepay for a year.
real
JDI can you see my charts ...they stopped coming in on my puter. you see the cci... look on the six month see the big breakout. I figure if the bollie's tighten up....its looking undercooked to me.
real
CPST Anyone ponder this one lately? Would like to compare opinions with others.
Closer Look w aroons
DSLN
The Boys of Summer... Don Henley
CPST How is this looking? Anybody? ITs way undercooked IMO
real
Its all cool I will send you pics... we have all summer :)
real